Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback